American Headache Society 65th Annual Scientific Meeting (AHS 2023) Austin, Texas 16 June 2023 - 18 June 2023 Fewer migraine days with dual therapy 17 Jul 2023 bởiElvira ManzanoElvira Manzano Combination therapy with an anti-CGRP* monoclonal antibody (mAB) and onabotulinumtoxinA may be more effective than either therapy in patients with chronic migraine, according to a new study.17 Jul 2023 Fremanezumab eases migraine and depressive symptoms 13 Jul 2023 bởiElvira ManzanoElvira Manzano Treatment with fremanezumab – an anticalcitonin gene-related peptide (CGRP) – reduces depressive symptoms in patients with migraine and comorbid major depressive disorder (MDD) in the UNITE trial.13 Jul 2023 1 1
